Key result
Asymptomatic adults with hepatic steatosis had a higher rate of MACEs than those without (10% vs 4%), with increased risk in those with CAD-RADS 1-2 (HR 2.3) and 3-5 (HR 2.1).
Why the study?
The long-term prognostic value of coronary CT angiography in asymptomatic adults with hepatic steatosis remains unknown.
Does the presence of hepatic steatosis increase the risk of major adverse cardiovascular events in asymptomatic adults undergoing CCTA?
Population
1013 participants with HS and 1940 participants without HS undergoing CCTA and unenhanced abdominal CT
Comparison
Participants with HS vs participants without HS
Design
Prospective cohort study
Follow-up
Median of 7.2 years
Authors
Loading...
Hepatic steatosis may flag higher MACE risk in asymptomatic adults with CAD on CCTA; leaves open independent prognostic value beyond CAD-RADS.
Cohort (n=2,953)
Does the presence of hepatic steatosis increase the risk of major adverse cardiovascular events in asymptomatic adults undergoing CCTA?
Absolute Event Rate: 10% vs 4%
In asymptomatic adults, hepatic steatosis is associated with a higher risk of MACE only in the presence of coronary artery disease on CCTA, while those with normal coronaries have excellent outcomes regardless of hepatic steatosis.
Yu et al. (2021) conducted a cohort in Asymptomatic adults with hepatic steatosis (n=2,953). Hepatic steatosis vs. Without hepatic steatosis was evaluated on Major adverse cardiovascular events (MACEs), defined as cardiac death, stroke, myocardial infarction, and angina requiring hospitalization. Asymptomatic adults with hepatic steatosis had a higher rate of MACEs than those without (10% vs 4%), with increased risk in those with CAD-RADS 1-2 (HR 2.3) and 3-5 (HR 2.1).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: